FY2025 EPS Estimates for Stereotaxis Raised by Roth Capital

Stereotaxis, Inc. (NYSEAMERICAN:STXS) – Investment analysts at Roth Capital boosted their FY2025 earnings per share estimates for shares of Stereotaxis in a note issued to investors on Monday, May 12th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.27) per share for the year, up from their previous forecast of ($0.30). The consensus estimate for Stereotaxis’ current full-year earnings is ($0.26) per share. Roth Capital also issued estimates for Stereotaxis’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.23) EPS.

Stereotaxis Trading Up 1.0%

Shares of STXS stock opened at $2.07 on Thursday. Stereotaxis has a twelve month low of $1.54 and a twelve month high of $2.72. The stock has a market capitalization of $175.39 million, a price-to-earnings ratio of -7.39 and a beta of 1.54. The stock has a fifty day simple moving average of $1.89 and a two-hundred day simple moving average of $2.07.

Insiders Place Their Bets

In other news, Director Paul J. Isaac bought 23,299 shares of the stock in a transaction on Thursday, March 6th. The stock was acquired at an average cost of $1.81 per share, for a total transaction of $42,171.19. Following the acquisition, the director now owns 49,066 shares of the company’s stock, valued at $88,809.46. This represents a 90.42% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 18.52% of the company’s stock.

Institutional Investors Weigh In On Stereotaxis

Hedge funds have recently made changes to their positions in the company. Independent Advisor Alliance lifted its stake in shares of Stereotaxis by 3.2% during the 1st quarter. Independent Advisor Alliance now owns 191,695 shares of the company’s stock worth $337,000 after purchasing an additional 5,900 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Stereotaxis during the 1st quarter worth $130,000. Deutsche Bank AG purchased a new stake in shares of Stereotaxis during the 1st quarter worth $82,000. Warberg Asset Management LLC lifted its stake in shares of Stereotaxis by 476.8% during the 1st quarter. Warberg Asset Management LLC now owns 333,622 shares of the company’s stock worth $587,000 after purchasing an additional 275,784 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Stereotaxis during the 1st quarter worth $37,000. 45.35% of the stock is currently owned by hedge funds and other institutional investors.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.